Danaher (DHR) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.

RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.

Danaher is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.

RBC Capital Markets resumed coverage on Danaher, with an outperform rating and a $200 price target.

Shares of Danaher were down 1.1% in Friday afternoon trading.

Price: 162.75, Change: -1.79, Percent Change: -1.09